Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: A meta-analysis of pharmacogenetic interactions

Molecular Psychiatry

Volumn 13, Issue 5, 2008, Pages 544-556

  Bakker, P R ^a,d   Van Harten, P N ^a   Van Os, J ^b,c  

^a Symfora Group Psychiatric Center   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d Medisch Centrum   (Netherlands)

Author keywords

Catechol O methyltransferase; Cytochrome P450 CYP1A2; Dopamine D2 receptor; Drug induced; Manganese superoxide dismutase; Tardive dyskinesia

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1A2; DOPAMINE 2 RECEPTOR; MANGANESE SUPEROXIDE DISMUTASE; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL TRIAL; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; META ANALYSIS; PATHOPHYSIOLOGY; PHARMACOGENETICS; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP1A2; DYSKINESIA, DRUG-INDUCED; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MUTAGENESIS, INSERTIONAL; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D2; SEQUENCE DELETION; SMOKING; SUPEROXIDE DISMUTASE;

EID: 42349094914     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4002142     Document Type: Article

References (93)

1. Sachdev PS. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am 2005; 28: 255-274, x.
2. Muller DJ, Shinkai T, De Luca V, Kennedy JL. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004; 4: 77-87.
3. Marsalek M. Tardive drug-induced extrapyramidal syndromes. Pharmacopsychiatry 2000; 33(Suppl 1): 14-33.
4. Abdolmaleky HM, Thiagalingam S, Wilcox M. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics 2005; 5: 149-160.
5. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533-1537.
6. Egger M, Smith GD. Meta-analysis. Potentials and promise. BMJ 1997; 315: 1371-1374.
7. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006; 83: 185-192.
8. van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand 1997; 96: 206-216.
9. Ellingrod VL, Schultz SK, Arndt S. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy 2002; 22: 1416-1419.
10. Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JP. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 2005; 15: 151-158.
11. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Lerer B, Nimgaonkar VL et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005; 75: 21-26.
12. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005; 5: 60-69.
13. Ozdemir V, Aklillu E, Mee S, Bertilsson L, Albers LJ, Graham JE et al. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother 2006; 7: 119-133.
14. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998; 155: 1207-1213.
15. Collier DA, Li T. The genetics of schizophrenia: glutamate not dopamine? Eur J Pharmacol 2003; 480: 177-184.
16. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
17. Jann MW. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy 2004; 24: 1759-1783.
18. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-1302.
19. Bray NJ, Buckland PR, Williams NM, Williams HJ, Norton N, Owen MJ et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 2003; 73: 152-161.
20. Handoko HY, Nyholt DR, Hayward NK, Nertney DA, Hannah DE, Windus LC et al. Separate and interacting effects within the Catechol-O-Methyltransferase (COMT) are associated with schizophrenia. Mol Psychiatry 2005; 10: 589-597.
21. Palmatier MA, Pakstis AJ, Speed W, Paschou P, Goldman D, Odunsi A et al. COMT haplotypes suggest P2 promoter region relevance for schizophrenia. Mol Psychiatry 2004; 9: 859-870.
22. Williams HJ, Owen MJ, O'Donovan MC. Is COMT a susceptibility gene for schizophrenia? Schizophr Bull 2007; 33: 635-641.
23. Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull 1999; 25: 731-740.
24. Lerer B. Pharmacogenetics of Psychotropic Drugs. Cambridge University Press: Cambridge, 2002 pp x, 446.
25. Accili D, Fishburn CS, Drago J, Steiner H, Lachowicz JE, Park BH et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci USA 1996; 93: 1945-1949.
26. Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G. D3 dopamine receptor MRNA is widely expressed in the human brain. Brain Res 1998; 779: 58-74.
27. Zai CC, Hwang RW, De Luca V, Muller DJ, King N, Zai GC et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10: 639-651.
28. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat 2004; 23: 540-545.
29. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 1991; 48: 648-654.
30. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK et al. D2 dopamine receptor gene (DRD2) Taq1 a polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7: 479-484.
31. Laruelle M, Gelernter J, Innis RB. D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol Psychiatry 1998; 3: 261-265.
32. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry 1998; 3: 256-260.
33. Jonsson EG, Nothen MM, Grunhage F, Farde L, Nakashima Y, Propping P et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry 1999; 4: 290-296.
34. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000; 152: 174-180.
35. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 2003; 116: 103-125.
36. Young RM, Lawford BR, Nutting A, Noble EP. Advances in molecular enetics and the prevention and treatment of substance misuse: implications of association studies of the A1 allele of the D2 dopamine receptor gene. Addict Behav 2004; 29: 1275-1294.
37. Cravchik A, Sibley DR, Gejman PV. Functional analysis of the human D2 dopamine receptor missense variants. J Biol Chem 1996; 271: 26013-26017.
38. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6: 577-582.
39. Ritchie T, Noble EP. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem Res 2003; 28: 73-82.
40. MacLeod SL, Tang YM, Yokoi T, Kamataki T, Doublin S, Lawson B. The role of a recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene. Proc Am Assoc Cancer Res 1998; 39: 396.
41. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449.
42. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5: 410-417.
43. Chong SA, Tan EC, Tan CH, Mythily. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003; 28: 185-189.
44. Fu Y, Fan CH, Deng HH, Hu SH, Lv DP, Li LH et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 2006; 27: 328-332.
45. Matsumoto C, Ohmori O, Shinkai T, Hori H, Nakamura J. Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr Genet 2004; 14: 209-213.
46. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 1999; 125: 803-808.
47. Hitzeroth A, Niehaus DJ, Koen L, Botes WC, Deleuze JF, Warnich L. Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 664-672.
48. Rosenblum JS, Gilula NB, Lerner RA. On signal sequence polymorphisms and diseases of distribution. Proc Natl Acad Sci USA 1996; 93: 4471-4473.
49. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochem Biophys Res Commun 1996; 226: 561-565.
50. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 2003; 13: 145-157.
51. Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 2005; 15: 311-319.
52. Herken H, Erdal ME, Boke O, Savas HA. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-O-methyltransferase gene. Eur Psychiatry 2003; 18: 77-81.
53. Lai IC, Wang YC, Lin CC, Bai YM, Liao DL, Yu SC et al. Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. J Neural Transm 2005; 112: 1107-1113.
54. Matsumoto C, Shinkai T, Hori H, Ohmori O, Nakamura J. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry Res 2004; 127: 1-7.
55. Han DH, Lee JH, Lee YS, Kee BS, Min KJ, Na C. The association between tardive dyskinesia induced by haloperidol and polymorphisms in the serotonin transporter gene and catecholamine-O-methyltransferase gene in Korean schizophrenic patients. Clin Psychopharmacol Neurosci 2005; 3: 16-21.
56. Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006; 16: 111-117.
57. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11: 2517-2530.
58. Chong SA, Tan EC, Tan CH, Mythily, Chan YH. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet 2003; 116B: 51-54.
59. de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005; 25: 448-456.
60. Lattuada E, Cavallaro R, Serretti A, Lorenzi C, Smeraldi E. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 2004; 7: 489-493.
61. Kaiser R, Tremblay PB, Klufmoller F, Roots I, Brockmoller J. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002; 7: 695-705.
62. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997; 41: 827-829.
63. Nakazono Y, Abe H, Murakami H, Koyabu N, Isaka Y, Nemoto Y et al. Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients. Int J Clin Pharmacol Ther 2005; 43: 163-171.
64. Guzey C, Scordo MG, Spina E, Landsem VM, Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. Eur J Clin Pharmacol 2007; 63: 233-241.
65. Xu XF, Zhang XB, Sha WW, Zhou CY. Association of the gene polymorphism of dopamine and serotonin 2A receptors with tardive dyskinesia in chronic schizophrenia. Zhongguo Linchuang Kangfu 2006; 10: 106-108.
66. Liou YJ, Lai IC, Liao DL, Chen JY, Lin CC, Lin CYet al. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr Res 2006; 86: 323-325.
67. Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105: 774-778.
68. Segman RH, Goltser T, Heresco-Levy U, Finkel B, Shalem R, Schlafman M et al. Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia. Pharmacogenomics J 2003; 3: 277-283.
69. Dolzan V, Plesnicar BK, Serretti A, Mandelli L, Zalar B, Koprivsek J et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am J Med Genet B Neuropsychiatr Genet 2007; 144: 809-815.
70. Schulze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105: 498-501.
71. -164A polymorphism and tardive dyskinesia. 2002. (Poster).
72. Shen H, He MM, Liu H, Wrighton SA, Wang L, Guo B et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 2007; 35: 1292-1300.
73. Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000; 23: 170-177.
74. Zhang Z, Zhang X, Hou G, Sha W, Reynolds GP. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res 2002; 36: 317-324.
75. Pae CU. Comments on 'Association between Ala-9Val polymorphism of MnSOD gene and schizophrenia' by O. Akyol et al. Progress in neuropsychopharmacology and biological psychiatry 29, 2005, 123-131. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 762-763.
76. Akyol O, Yanik M, Elyas H, Namli M, Canatan H, Akin H et al. Association between Ala-9Val polymorphism ofMn-SOD gene and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 123-131.
77. Galecki P, Pietras T, Szemraj J. Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland. Psychiatr Pol 2006; 40: 937-948.
78. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707-747.
79. Thomas DC. Statistical Methods in Genetic Epidemiology. Oxford University Press: New York, 2004.
80. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006; 26: 365-384.
81. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron 2006; 52: 139-153.
82. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005; 8: 411-425.
83. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-119.
84. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-425.
85. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
86. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
87. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van OJ. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. J Clin Psychiatry 2005; 66: 1130-1133.
88. Procyshyn RM, Kennedy NB, Tse G, Thompson B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001; 46: 334-339.
89. Broekema WJ, de Groot I, van Harten PN. Simultaneous Prescribing of Atypical Antipsychotics, Conventional Antipsychotics and Anticholinergics-a European Study. Pharm World Sci 2007; 29: 126-130.
90. Malhotra AK, Murphy Jr GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780-796.
91. Insel TR, Lehner T. A new era in psychiatric genetics? Biol Psychiatry 2007; 61: 1017-1018.
92. Ozdemir V, Williams-Jones B, Glatt SJ, Tsuang MT, Lohr JB, Reist C. Shifting emphasis from pharmacogenomics to theragnostics. Nat Biotechnol 2006; 24: 942-946.
93. Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, Boffetta P et al. A road map for efficient and reliable human genome epidemiology. Nat Genet 2006; 38: 3-5.